Can a common drug stop chemo weight loss in stomach cancer?
NCT ID NCT07581405
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a low dose of olanzapine, a drug often used for nausea, can help gastric cancer patients avoid weight loss and keep their appetite during chemotherapy before surgery. About 26 adults with stomach cancer will be randomly assigned to receive olanzapine or standard care alone. The goal is to see if olanzapine improves nutrition and quality of life during treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Olanzapine
What this could lead to
If it works, this could offer a simple way to help gastric cancer patients keep their weight and appetite up during chemotherapy.
What could go wrong
This is a small, early-phase trial with only 26 people, so results may not apply widely. Olanzapine can cause side effects like drowsiness or increased blood sugar.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Illinois Cancer Center
Chicago, Illinois, 60612, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact